This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Milford, MA-based, Waters Corp. is an analytical instrument manufacturer and offers practical and sustainable products for laboratory-dependent organizations. Moreover, Waters provides analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies. The company’s products are used by pharmaceutical, life science, biochemical, industrial, academic and government customers, working in research and development, quality assurance and other laboratory applications. The company operates in Asia, Americas and Europe. Waters organizes its business into two operating segments: Waters Division and TA Division. Waters Division (88.8% of total revenues in 2019) - High Performance and Ultra Performance Liquid Chromatography (HPLC and UPLC). TA Division (11.2% of total revenues in 2019)- Thermal Analysis, Rheometry and Calorimetry.
Why Is Waters (WAT) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphering Waters (WAT) International Revenue Trends
by Zacks Equity Research
Explore how Waters' (WAT) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Compared to Estimates, Waters (WAT) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Waters (WAT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Waters (WAT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 3.14% and 1.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Sensus Healthcare (SRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) second-quarter 2024 results are likely to reflect strength in the large molecule and PFAS testing markets amid weakening demand in China.
Analysts Estimate Waters (WAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQV vs. WAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IQV vs. WAT: Which Stock Is the Better Value Option?
Agilent (A) Boosts Reach to Lab Researchers With New Devices
by Zacks Equity Research
Agilent (A) boosts its presence in the mass spectrometry market with the launch of the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell.
Why Is Waters (WAT) Down 5.1% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Waters (WAT) Expands Mass Spectrometer Portfolio With Xevo MRT
by Zacks Equity Research
Waters (WAT) boosts MS offerings with the launch of Xevo MRT, strengthening its Waters operating segment's portfolio.
Waters (WAT) International Revenue in Focus: Trends and Expectations
by Zacks Equity Research
Examine Waters' (WAT) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Waters (WAT) Q1 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) first-quarter results are hurt by weak end-market momentum and softness in Asia.
Compared to Estimates, Waters (WAT) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Waters (WAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 6.90% and 3.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) first-quarter 2024 results are likely to reflect strength in the large molecule and PFAS testing markets amid weakening demand in China.
Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unlocking Q1 Potential of Waters (WAT): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Waters (WAT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Earnings Preview: Waters (WAT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) Boosts Waters Operating Segment With HPLC System
by Zacks Equity Research
Waters (WAT) launches Alliance iS Bio HPLC system to improve efficiency across biopharma QC laboratories, boosting its Waters Operating segment.
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Waters (WAT) Boosts PFAS Testing Solutions With New Cartridges
by Zacks Equity Research
Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.
Waters (WAT) Boosts Portfolio Strength With Rheo-IS Accessory
by Zacks Equity Research
Waters (WAT) unveils Rheo-IS accessory for its TA Instruments Discovery Hybrid Rheometers, bolstering its overall portfolio.
Why Is Waters (WAT) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.